概括
在患有晚期KRASG12C非小细胞肺癌的患者中,Adagrasib证明了持久的有效性和可控的安全性. 这种KRASG12C抑制剂提供了持久的疗效,大约三分之一的患者在两年内还活着.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 非小细胞肺癌 (NSCLC) 仍然是全球癌症相关死亡的主要原因.
- KRAS突变,特别是KRASG12C,是NSCLC常见的驱动因素,但历史上缺乏向疗法.
研究的目的:
- 评估KRASG12C抑制剂阿达格拉西布的长期疗效和安全性,对先前接受过治疗的先进KRASG12C突变NSCLC的患者.
- 报告Krystal-1试验的结果在2年的随访时间.
主要方法:
- KRYSTAL-1是一个正在进行的临床试验,研究KRASG12C突变NSCLC患者的阿达格拉西布.
- 提出的数据是基于2年的随访,评估整体存活率和新出现的毒性.
主要成果:
- 在先前接受过治疗的晚期KRASG12CNSC癌症患者中,阿达格拉西布证明了持久的疗效.
- 在两年后,大约三分之一的患者仍然活着,这表明持续的治疗效益.
- 没有观察到新的意想不到的毒性,这表明阿达格拉西布的可管理的长期安全性.
结论:
- 在晚期KRASG12CNSC的患者中,Adagrasib提供了持久的临床益处.
- 阿达格拉西布的长期安全性似乎是可以控制的,这支持其在这个患者群体中继续使用.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
相关概念视频
The Ras Gene
6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
